Novel Synovial Role in Pathogenesis of Gout
Novel Synovial Role in Pathogenesis of Gout
批准号:
9810080
负责人:
Robert A. Terkeltaub
金额:
$18.62万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-08-01 至 2021-07-31
关键词:
ABCG2 geneADAMTSAcuteAgeAmino Acid Sequence DatabasesAnabolismAreaArthritisAutomobile DrivingBiologicalBiological MarkersBiologyCandidate Disease GeneCellsCharacteristicsChronicClinicalCrystal FormationCrystallizationCustomDNA SequenceDataDefectDepositionDevelopmentDiseaseDropsEnzymesExtracellular MatrixFemaleFibroblastsFlareFrequenciesGenerationsGenetic studyGenomic DNAGenomic Data CommonsGenomicsGlycoproteinsGoutGouty ArthritisHip region structureHyperuricemiaImageInflammationInflammatoryInflammatory ResponseIntegral Membrane ProteinInterleukin-1Interphalangeal joint of toeJointsKnock-outKnowledgeLeadLightLightingLinkLubricantsMediator of activation proteinMetabolic DiseasesMetabolismMinorityMolecular ChaperonesMorbidity - disease rateMucin 1 proteinMucinsMutationNatureO-Glycans Biosynthesis PathwayOutcomePainPalpableParentsPathogenesisPathway interactionsPatientsPeptide HydrolasesPhenotypePlayPolysaccharidesProcessProteomicsPublic HealthPumpQuantitative Trait LociRiskRoleSamplingSerumSmall Interfering RNASpecimenSusceptibility GeneSynovial MembraneSynovitisTestingTherapeuticTissuesToesTransfectionUrateUric AcidVariantWorkarthropathiescell behaviorclinical phenotypeenzyme pathwayexperimental studygenetic approachgenome wide association studyglycoprotein biosynthesisglycoproteomicsglycosylationhigh rewardhigh riskinhibitor/antagonistjoint injuryknock-downlubricinmembernew therapeutic targetnovelnovel markernovel strategiespreventprobandpurine metabolismresponsereverse geneticssialylationsubcutaneoustargeted biomarkerurate transporter
中文摘要
摘要
英文摘要
Abstract
Gout is a highly prevalent disease manifesting most commonly as acute, episodic synovitis that
characteristically is excruciatingly painful. Gout continues to grow as a public health problem. The disorder is
promoted by elevated body stores of uric acid, and the clinical phenotypes of arthritis are caused by
inflammatory responses associated with articular deposits of urate crystals. However, gout develops in only a
minority subset of hyperuricemic subjects. Moreover, clinical responses to deposited urate crystals are highly
variable, including the frequency and extent of acute arthritis, and progression to palpable subcutaneous tophi,
chronic arthritis, and erosive joint damage. There is unmet need to define new therapy targets and biomarkers
for incident gout and progression to erosive joint disease. The rationale for this high risk/high reward
application is that by clarifying major gaps in knowledge in these areas, the work will be paradigm-shifting, and
potentially identify new targets to help prevent and limit gout-associated morbidity. Emerging findings, including
from certain arthropathies other than gout, suggest that altered extracellular matrix O-linked glycoprotein
components such as the mucin-type boundary lubricant lubricin, and active urate pumping into the joint by an
unidentified transport mechanism play a role in development of gout. Our scientific premise is that, in synovial
fibroblast lining cells (FLS), mechanistically linked alterations in lubricin and other mucin-type extracellular
matrix O-glycoproteins and increased urate secretion are in a mechanistic lop that promotes “common gout”,
and progression to chronic, destructive synovitis. We will use primarily a combined candidate gene and reverse
genetics approach to analyze a highly unusual observation, specifically a case of gout as an “experiment of
nature”. The proband, an otherwise healthy female without hyperuricemia, at age 22 had onset of destructive
hip synovitis, and asymmetric acute gouty arthritis flares of small and intermediate joints with classic toe joint
gout erosions, and gout definitively confirmed. Collective preliminary data for proband whole genomic DNA,
and serum glycomics, proteomics, and glycoproteomics suggest dysregulation in biosynthesis of lubricin and
other mucin-type O-glycoproteins that normally serve as constitutive inhibitors of inflammation. Gene
candidates are highly enriched in the “reactome” of TMEM171, an incompletely characterized transmembrane
molecule implicated in urate transport and recently defined as a gout susceptibility gene. Specifically, the
TMEM171 reactome comprises over 20 molecules involved in glycoprotein biosynthesis, more than 10
mucintype. O-glycoproteins, and over 20 ADAMTS protease superfamily members. The work aims to illuminate
novel intersections between synovial extracellular matrix biology, urate metabolism and transport, tophus
formation, and synovitis. Positive impact includes building a new disease paradigm for “common gout”,
potential new biomarkers, and possible gout therapeutics from the novel class of O-glycoprotein agents.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Intersections of matrix biology with inflammation in a new model of gout
-
批准号:10579760
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2022
-
负责人:Robert A. Terkeltaub
-
依托单位:
Rheumatic Diseases Research Training Grant
-
批准号:8660292
-
项目类别:
-
资助金额:$25.26万
-
财政年份:2013
-
负责人:Robert A. Terkeltaub
-
依托单位:
Rheumatic Diseases Research Training Grant
-
批准号:9699169
-
项目类别:
-
资助金额:$15.18万
-
财政年份:2013
-
负责人:Robert A. Terkeltaub
-
依托单位:
Rheumatic Diseases Research Training Grant
-
批准号:9919502
-
项目类别:
-
资助金额:$30.7万
-
财政年份:2013
-
负责人:Robert A. Terkeltaub
-
依托单位:
Rheumatic Diseases Research Training Grant
-
批准号:8849851
-
项目类别:
-
资助金额:$22.54万
-
财政年份:2013
-
负责人:Robert A. Terkeltaub
-
依托单位:
Rheumatic Diseases Research Training Grant
-
批准号:8475141
-
项目类别:
-
资助金额:$24.48万
-
财政年份:2013
-
负责人:Robert A. Terkeltaub
-
依托单位:
Rheumatic Diseases Research Training Grant
-
批准号:9062290
-
项目类别:
-
资助金额:$24.36万
-
财政年份:2013
-
负责人:Robert A. Terkeltaub
-
依托单位:
Innate Inflammation in Osteoarthritis
-
批准号:8461078
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Robert A. Terkeltaub
-
依托单位:
Innate Inflammation in Osteoarthritis
-
批准号:8698319
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Robert A. Terkeltaub
-
依托单位:
Innate inflammation in osteoarthritis
-
批准号:9351732
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Robert A. Terkeltaub
-
依托单位:
Innate inflammation in osteoarthritis
-
批准号:9898282
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Robert A. Terkeltaub
-
依托单位:
Project 1: AMPK and Inflammation in Gout
-
批准号:10263204
-
项目类别:
-
资助金额:$28.29万
-
财政年份:2012
-
负责人:Robert A. Terkeltaub
-
依托单位:
Innate Inflammation in Osteoarthritis
-
批准号:8330368
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Robert A. Terkeltaub
-
依托单位:
Project 1: AMPK and Inflammation in Gout
-
批准号:10017003
-
项目类别:
-
资助金额:$22.67万
-
财政年份:2012
-
负责人:Robert A. Terkeltaub
-
依托单位:
Transglutaminase 2 in Arterial Calcification and Atherosclerosis
-
批准号:7388360
-
项目类别:
-
资助金额:$34.63万
-
财政年份:2008
-
负责人:Robert A. Terkeltaub
-
依托单位:
Transglutaminase 2 in Arterial Calcification and Atherosclerosis
-
批准号:7766945
-
项目类别:
-
资助金额:$34.63万
-
财政年份:2008
-
负责人:Robert A. Terkeltaub
-
依托单位:
Transglutaminase 2 in Arterial Calcification and Atherosclerosis
-
批准号:7625105
-
项目类别:
-
资助金额:$34.63万
-
财政年份:2008
-
负责人:Robert A. Terkeltaub
-
依托单位:
Chondrocyte S100/Calgranulins and RAGE in Osteoarthritis
-
批准号:7433195
-
项目类别:
-
资助金额:$23.21万
-
财政年份:2006
-
负责人:Robert A. Terkeltaub
-
依托单位:
Chondrocyte S100/Calgranulins and RAGE in Osteoarthritis
-
批准号:7233960
-
项目类别:
-
资助金额:$23.69万
-
财政年份:2006
-
负责人:Robert A. Terkeltaub
-
依托单位:
Chondrocyte S100/Calgranulins and RAGE in Osteoarthritis
-
批准号:7137685
-
项目类别:
-
资助金额:$24.39万
-
财政年份:2006
-
负责人:Robert A. Terkeltaub
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Decorin调控ADAMTS12 m6A甲基化与IL12B/VEGF免疫互作介导肥胖合并妊娠期糖尿病子代心血管疾病的作用研究
-
批准号:2026JJ81694
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:罗慧
-
依托单位:
ADAMTS1靶向MDM2/RBM15/hnRNPC/p16轴诱导心脏衰老的作用机制研究
-
批准号:2026JJ81629
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:蒋路平
-
依托单位:
肠道菌群色氨酸代谢产物IPA通过NSUN5/ADAMTS-1途径调控胶原降解抑制肺纤维化
-
批准号:2026JJ81748
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:贺兼斌
-
依托单位:
TGF-β1/SMAD2调节ADAMTS1抑制HDAC6介导心肌梗死后心肌纤维化的机制研究
-
批准号:2025JJ80555
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:陈春
-
依托单位:
磁共振/NIR荧光双模态探针的构建及对ADAMTS1介导心肌梗死后心肌纤维化的可视化及定量评估研究
-
批准号:2025JJ80588
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:周俊杰
-
依托单位:
基于ADAMTS7启动子区基因多态性探讨
USF1/ADAMTS7通路在动脉粥样硬化易损
斑块中的作用及分子调控机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:陈林发
-
依托单位:
ADAMTS19介导P65泛素化抑制胃癌血管生
成的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:江英铭
-
依托单位:
ADAMTS4调控AKT1-S473去磷酸化激活线粒体凋亡加重脓毒症心肌病的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2024
-
负责人:汤晓燕
-
依托单位:
ADAMTS5通过RasGRP1/CHI3L1通路调节胃癌血管生成、侵袭迁移、重塑免疫微环境的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:黄进团
-
依托单位:
Lnc RNA ADAMTS9-AS2/EZH2调控ENO1剪接模式影响膀胱癌细胞糖酵解活性的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位: